Chief Data Scientist, Zuellig Pharma, Singapore
Faced with lower success rates in R&D and stagnant pipelines the pharmaceutical industry is quietly evolving a new business model. The digital revolution and the emergence of big data with the computing power to analyse it, is being seized upon by pharma/biotech companies as a way better managing clinical trials and biomedical research.
The McKinsey Global Institute estimates that big data strategies could generate $100 billion in value in the US alone.
Electronic patient records, digital sensors and devices on the factory floor and the patients, online sales and marketing, as well as digitising unstructured information sources all have the potential to transform the design of clinical trials and biomedical research.
The future could see patients enrolling on clinical trials via social media – bypassing the doctor’s surgery or predictive modelling would identify candidate molecules that can be successfully developed into drugs.
2017 speakers include
Senior Consultant and Surgical Director, Comprehensive Liver Cancer clinic, National Cancer Centre Singapore
The challenges, opportunities and strategies for using big data in clinical trial and biomedical research are the subject of this Clinical Trials & Biomedical Research Congress: Asia. Discover more about this meeting…